{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:22Z","timestamp":1793814082825,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e25463","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T20:48:21Z","timestamp":1706820501000},"page":"e25463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Activated CD4 T cells\/Tregs derived immune-metabolism signature provide precise prognosis assessment for gastric cancer and beneficial for treatment option"],"prefix":"10.1016","volume":"10","author":[{"given":"Junyu","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-8245","authenticated-orcid":false,"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.heliyon.2024.e25463_bib1","first-page":"1549","article-title":"Toward a better understanding of T cells in cancer","volume":"39","author":"Oh","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e25463_bib2","first-page":"14","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25463_bib3","first-page":"2837","article-title":"Tissue-resident memory CD4+ T cells play a dominant role in the initiation of antitumor immunity","volume":"208","author":"Zhang","year":"2022"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25463_bib4","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021"},{"issue":"7900","key":"10.1016\/j.heliyon.2024.e25463_bib5","first-page":"328","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25463_bib6","first-page":"6323","article-title":"The regulatory T cell family: distinct subsets and their interrelations","volume":"171","author":"Jonuleit","year":"2003"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25463_bib7","first-page":"2080","article-title":"Nishikawa HJCs: regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25463_bib8","first-page":"1140","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e25463_bib9","article-title":"Pyroptosis, apoptosis, and necroptosis molecular subtype derived prognostic signature universal applicable for gastric cancer-A large sample and multicenter retrospective analysis","volume":"149","author":"Huo","year":"2022"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25463_bib10","first-page":"427","article-title":"Biophysics: immune analysis and small molecule drug prediction of hepatocellular carcinoma based on single sample gene set enrichment analysis","volume":"80","author":"Huang","year":"2022"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25463_bib11","first-page":"2612","article-title":"Levine DAJNc: Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e25463_bib12","first-page":"1","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"gene set variation analysis for microarray and RNA-seq data"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25463_bib13","first-page":"1747","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018"},{"issue":"175","key":"10.1016\/j.heliyon.2024.e25463_bib14","article-title":"Three differential expression analysis methods for RNA sequencing: limma","author":"Liu","year":"2021","journal-title":"EdgeR, DESeq2."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25463_bib15","first-page":"284","article-title":"He Q-YJOajoib: clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012"},{"issue":"43","key":"10.1016\/j.heliyon.2024.e25463_bib16","first-page":"15545","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005"},{"key":"10.1016\/j.heliyon.2024.e25463_bib17","first-page":"80716","article-title":"Unsupervised K-means clustering algorithm","volume":"8","author":"Sinaga","year":"2020"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25463_bib18","first-page":"345","article-title":"Model selection and Akaike's information criterion (AIC): the general theory and its analytical extensions","volume":"52","author":"Bozdogan","year":"1987"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25463_bib19","first-page":"898","article-title":"Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma","volume":"12","author":"Huo","year":"2023"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25463_bib20","first-page":"248","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25463_bib21","first-page":"bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25463_bib22","first-page":"269","article-title":"Immunotherapy: past, present and future","volume":"9","author":"Waldmann","year":"2003"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25463_bib23","first-page":"325","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018"},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e25463_bib24","first-page":"5","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25463_bib25","first-page":"635","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25463_bib26","first-page":"200","article-title":"Adoptive immunotherapy of cancer using CD4+ T cells","volume":"21","author":"Muranski","year":"2009"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25463_bib27","first-page":"2701","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021"},{"issue":"6184","key":"10.1016\/j.heliyon.2024.e25463_bib28","first-page":"641","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25463_bib29","first-page":"556","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity","volume":"177","author":"Binnewies","year":"2019"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e25463_bib30","first-page":"2994","article-title":"Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment","volume":"27","author":"Granito","year":"2021"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024014944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024014944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:19:11Z","timestamp":1775456351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024014944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024014944"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25463","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated CD4 T cells\/Tregs derived immune-metabolism signature provide precise prognosis assessment for gastric cancer and beneficial for treatment option","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e25463"}}